Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

about

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

Item

http://www.wikidata.org/entity/Q47225363

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

@en

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

@nl

type

Item

label

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

@en

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

@nl

prefLabel

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

@en

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

@nl

P1476

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

@en

P2093

Guoyan Qi

http://www.w3.org/2001/XMLSchema#string

Hongxia Yang

http://www.w3.org/2001/XMLSchema#string

Xiaojing Zhang

http://www.w3.org/2001/XMLSchema#string

Yinping Xue

http://www.w3.org/2001/XMLSchema#string

Yongzhao Li

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.

Comparison of patterns of relapse in thymic carcinoma and thymoma.

Follow-up study of thymomas with special reference to their clinical stages.

Obesity and diabetes in the developing world--a growing challenge.

Prevalence of hypertension in china: a cross-sectional study.

Carcinoma showing thymic-like elements--a rare malignancy of the thyroid gland.

Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.

The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes.

Myasthenia gravis: subgroup classification and therapeutic strategies.

P304

403-408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1515/MED-2017-0058

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29318185

http://www.w3.org/2001/XMLSchema#string

P921

myasthenia gravis

P932

5757353

http://www.w3.org/2001/XMLSchema#string